Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
2646 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-02-13 (endpts.com)
Biogen downplays capacity for M&A; Roche's SMA drug is approved as a tablet
Biotech news roundup: Odyssey layoffs, GSK relocates vaccine R&D, Aligos raises $105M, Terrain Bio launches, Gates Foundation backs antibiotics research, Neuphoria gets Merck milestone
Read more
2025-02-13 (deraktionaer.de)
The deepest stood since 2013! Biogen share rushes into the basement - the shareholder
Disappointing numbers have been pressing the biogen's biogenic stock for more than one decade. Above all, the multiple sclerosis business and the proceeds with the medication of Skyclary's, which the company incorporated through the takeover of Reata, remained behind the expectations of the market. There is also a weak view.
Read more
2025-02-08 (endpts.com)
Q4 earnings updates; Biogen details revised research strategy; RFK Jr. advances out of Senate committee; and more
Q4 earnings updates: BMS plans $2B in cuts, AZ makes pipeline changes, Merck pauses Gardasil in China, Pfizer eyes M&A. RFK Jr. advances for HHS role, Biogen talks R&D strategy.
Read more
2025-01-29 (tipranks.com)
M&A News: Sage Rejects Biogen’s $469M Takeover Bid over Valuation Concerns - TipRanks.com
Biopharmaceutical company Sage Therapeutics ($SAGE) has rejected Biogen’s ($BIIB) $469 million takeover offer, citing valuation concerns in the proposal. Biogen, wh...
Read more
2025-01-20 (edisongroup.com)
BB Biotech — A positive start to a promising year -
BB Biotech (BION) is the largest biotech investor among its investment company peers.
Read more
2025-01-18 (pharmaphorum.com)
Sage sues Biogen after unsolicited takeover bid |
Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal
Read more![[JP Morgan] Biogen ‘No M&A for the time being’… Alzheimer's drug 'Lechembe' expected to do well < Zoom in on academic conference < Text of article -](https://images.businessradar.com/articles/de417211-5459-473e-8894-cc3efad60457)
2025-01-17 (thebionews.net)
[JP Morgan] Biogen ‘No M&A for the time being’… Alzheimer's drug 'Lechembe' expected to do well < Zoom in on academic conference < Text of article -
[The Bio Reporter Seong Jae-jun] Biogen, a multinational pharmaceutical company, has confirmed that it will not engage in mergers and acquisitions (M&A) for the time being. This appears to be a reason to be more cautious in utilizing capital in a situation where products launched last year, such as a treatment for Alzheimer's disease, are expected to do well. Chris Viehb
Read more
2024-12-11 (labiotech.eu)
Biotech in 2024: A retrospective
2024 is coming to a close and it is time to look at how biotech performed this year. Was it a triumph or a year of cautious optimism?
Read more
2024-10-29 (statnews.com)
GSK acquires autoimmune drug candidate
GSK said it acquired an experimental therapy from Chimagen Biosciences that it aims to test in different forms of lupus, and possibly other autoimmune diseases. GSK paid $300 million upfront, with additional payments possible if certain targets are met.
Read more